Expertise in
9
conditions

Francesco L. Giorgino

Bari, IT 
Expertise in
9
conditions
Bari, IT 

Overview

Francesco Giorgino practices practicing medicine in Bari, Italy.

Mr. Giorgino is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Obesity, and Low Blood Sugar.

He is actively involved in clinical research, co-authoring 253 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Bari, Italy
Other Locations
Puglia, Italy
Rome, 00161, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Telemedicine-based Intervention Study Involving Real-time and Anywhere Transmission of Blood Glucose Data to a Decision Supported Software-assisted Server With Web-based Analysis of Data and Medical Feedback on Metabolic Control.
A Telemedicine-based Intervention Study Involving Real-time and Anywhere Transmission of Blood Glucose Data to a Decision Supported Software-assisted Server With Web-based Analysis of Data and Medical Feedback on Metabolic Control.
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Procedure
Study Phase: Not Applicable
View 4 Less Clinical Trials

253 Total Publications

Comment on Hespanhol et al. Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Comment on Hespanhol et al. Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Journal: Diabetes care
Published: July 20, 2026

Frequently Asked Questions about Francesco L. Giorgino

Is Francesco L. Giorgino a top-rated expert for Type 2 Diabetes (T2D)?

MediFind is an objective health platform that identifies experts based on real-world data. Francesco L. Giorgino is classified as an Elite expert for Type 2 Diabetes (T2D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Francesco L. Giorgino participate in research or clinical trials?

Yes. Francesco L. Giorgino has published 253 articles and abstracts on conditions like Type 2 Diabetes (T2D). You can view a list of Francesco L. Giorgino's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Giorgino's expertise for a condition
ConditionClose
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile